Innate Pharma Advances Lacutamab Toward Accelerated Approval for Rare T-Cell Lymphomas
Key Insights
Innate Pharma will host an investor event on October 28, 2025, to discuss lacutamab's path to potential accelerated approval in Sézary syndrome (search) based on Phase 2 TELLOMAK trial data.
The first-in-class anti-KIR3DL2 (search) antibody has received FDA Fast Track, EMA PRIME, and Breakthrough Therapy designations for treating cutaneous T-cell lymphoma (search) patients with high unmet medical needs.
Real-world claims data reveals a larger eligible CTCL patient population in the U.S. than previously reported, strengthening the commercial opportunity as the company prepares for Phase 3 initiation.
Innate Pharma SA announced it will host an analyst and investor event on October 28, 2025, to showcase the clinical and commercial potential of lacutamab, its lead proprietary immunotherapy positioned for potential accelerated approval in Sézary syndrome (search) (SS). The event will feature key opinion leader presentations and real-world market data supporting the drug's advancement toward Phase 3 trials in cutaneous T-cell lymphoma (search) (CTCL).
The virtual and in-person event, scheduled from 8:00 a.m. to 10:00 a.m. ET at the Park Terrace Hotel on Bryant Park in New York, will include presentations from Pierluigi Porcu, M.D., Division Chief for Hematology and BMT at University of Kentucky and internationally recognized T-cell lymphoma expert. Dr. Porcu will discuss results from the Phase 2 TELLOMAK trial, which evaluated lacutamab in patients with relapsed or refractory CTCL.
Regulatory Pathway and Market Opportunity
Jonathan Dickinson, Chief Executive Officer of Innate Pharma, emphasized the drug's potential impact: "We look forward to engaging with the investor community in New York to share the latest updates and perspectives on lacutamab, a product which has the potential to meaningfully improve outcomes and quality of life for CTCL patients with high unmet medical needs while creating significant value for shareholders."
The company has received encouraging initial feedback from the FDA on its proposed regulatory pathway, which could potentially include accelerated approval for Sézary syndrome (search). Lacutamab is positioned for accelerated approval in SS once the confirmatory study in CTCL is underway, with the confirmatory Phase 3 protocol nearing completion.
ZS Associates (search), leading experts in life sciences and healthcare markets, will present real-world claims data describing the eligible U.S. CTCL patient population. According to Innate Pharma, new real-world data shows a larger eligible CTCL population in the U.S. than previously reflected in public data, further reinforcing the company's commitment to advancing lacutamab for patients.
Clinical Development and Regulatory Status
Lacutamab is a first-in-class anti-KIR3DL2 (search) antibody developed for CTCL and peripheral T-cell lymphoma (search) (PTCL). CTCL represents a group of rare non-Hodgkin lymphomas (search) that develop in the skin and severely affect patients' quality of life. Sézary syndrome (search) is described as a rare and aggressive leukemic form with poor survival, while mycosis fungoides (search) is the most common subtype, with advanced stages associated with poor outcomes.
Data from the Phase 2 TELLOMAK trial in CTCL demonstrated durable activity, a favorable safety profile, and improvements in patients' quality of life. The program has achieved significant regulatory milestones, including Fast Track designation from the FDA, PRIME designation from the EMA for SS, and Orphan Drug designation in both the US and EU for CTCL. Most recently, lacutamab received Breakthrough Therapy Designation for SS.
Company Portfolio and Partnerships
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its antibody-engineering expertise, the company has developed innovative therapeutic approaches, including Antibody Drug Conjugates (ADC), monoclonal antibodies (mAbs) and multi-specific NK Cell Engagers through its proprietary ANKET® (Antibody-based NK cell Engager Therapeutics) platform.
The company's portfolio includes IPH4502, a differentiated Nectin-4 (search) ADC in development in solid tumors, lacutamab, and monalizumab, an anti-NKG2A (search) antibody developed in collaboration with AstraZeneca in non-small cell lung cancer. Innate Pharma maintains partnerships with biopharmaceutical companies such as Sanofi and AstraZeneca, as well as renowned research institutions.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. The company continues to advance its pipeline while preparing for the potential commercial launch of lacutamab in the rare T-cell lymphoma space.